Roy S. Herbst MD, PhD

Ensign Professor of Medicine (Medical Oncology) and Professor of Pharmacology; Chief of Medical Oncology, Yale Cancer Center and Smilow Cancer Hospital at Yale-New Haven; Associate Director for Translational Research, Yale Cancer Center; Clinical Research Program Leader, Thoracic Oncology Program, Yale Cancer Center

Specialties & Subspecialties

Cancer Center, Yale: Thoracic Oncology Program

Medical Oncology

Education & Training

  • M.S., Yale University (1984)
  • B.S., Yale University (1984)
  • Ph.D., Rockefeller University (1990)
  • M.D., Cornell University Medical College (1991)
  • MMS, Harvard University (1997)
  • Residency, Brigham and Women`s Hospital , Internal Medicine  (1992 - 1994)
  • Fellowship, Dana Farber Cancer Institute , Medical Oncology  (1994 - 1997)
  • Fellowship, Brigham and Women`s Hospital , Medical Hematology  (1996 - 1997)

Patient Care

Accepts New Patients? Yes | Patient Type: Adult | Accepts referrals from patients


Clinical Interests

Lung cancer; Thoracic Oncology; Personalized Cancer Medicine; Clinical Trials for Lung cancer; Tumor profiling; Tumor biomakers


Cancers Treated

Lung


Board Certifications

  • Medical Oncology, Board Certified (1997)

Clinical Trials

Conditions Study Title
Breast Cancer (ER, PR, and HER2 negative), Colorectal Cancer, Endometrial Cancer, Gastric Adenocarcinoma, Glioblastoma Multiforme, Head/ Neck Squamous Cell Carcinoma, Melanoma, Non-Small Cell Lung Cancer (NSCLC), Ovarian Cancer, Prostate Cancer, Brain and Nervous System, Breast - Female, Breast - Male, Colon, Lip, Oral Cavity and Pharynx, Lung, Melanoma, skin, Other Female Genital, Ovary, Prostate, Rectum, and Stomach A Phase I/IIa, First Time in human, open-label dose-escalation study of GSK2636771 in subjects with advanced solid tumors with PTEN deficiency
Lung A Phase 1b Open-label Study to Evaluate the Safety and Tolerability of MEDI4736 in Combination with Tremelimumab in Subjects With Advanced Non-Small Cell Lung Cancer
Bladder, Breast - Female, Lung, Pancreas, and Stomach A Phase 1/2, Open-label Study of Nivolumab Monotherapy or Nivolumab combined with Ipilimumab in Subjects with Advanced or Metastatic Solid Tumors
Lung and Melanoma, skin A Phase 2 Study of MK-3475 in patients with metastatic melanoma and non-small cell lung cancer with untreated brain metastases
Lung A Phase 2b, Randomized, Double-blind Study Comparing Tremelimumab to Placebo in Second- or Third-line Treatment of Subjects with Unresectable Pleural or Peritoneal Malignant Mesothelioma

More Clinical Trials...

Edit Profile